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JOURNAL OF HEPATOLOGYReply to: ‘‘Underestimation of occult hepatitis C virus infection
in chronic haemodialysis and kidney transplant patients’’
To the Editor:
We thank Carreno et al. for their interest in our study regarding
occult hepatitis C virus (HCV) infection in haemodialysis and
kidney transplant patients and appreciate their comments as
they reﬂect the complexity and controversy of data available on
the topic of occult HCV infection [1]. Their group has provided
evidence on the presence of occult HCV infection in patients on
chronic haemodialysis in Spain [2]. However, it must be noted
that several studies have failed to conﬁrm occult HCV infection
under various circumstances using particularly sensitive tests
[3–5]. Reports on detection of HCV proteins in patients with
occult HCV infection need to be interpreted with caution in
respect of the methods used and results of other studies [3].
The method used by Carreno et al. included serial dilutions of
the isolated RNA that cannot be considered a gold standard due
to the limit of detection of HCV RNA by an in-house reverse tran-
scription PCR method [5]. We used the highly sensitive HCV RNA
transcription-mediated ampliﬁcation (TMA) assay for the detec-
tion of HCV RNA in peripheral blood mononuclear cells (PBMC).
Furthermore, the authors tested for occult HCV infection only in
selected haemodialysis patients with abnormal liver enzyme
values, whereas we did a prevalence study in a large number
of haemodialysis and kidney transplant patients, irrespective of
their liver function status, in order to study the potential role of
routine screening for occult HCV infection in these patients. In
response to the authors’ criticism of not studying anti-HCV posi-
tive and anti-HCV negative patients separately, we would like to
clarify that we did look at both HCV-positive and HCV-negative
cases separately and did not ﬁnd any prevalence of occult HCV
infection in any of the HCV-positive cases. The results are shown
in Table 2 and Fig. 1 of our paper [1].
The authors argue that ‘‘for HCV RNA detection in PBMC, integ-
rity of the isolated RNA and the amount used for viral RNA detec-
tion are crucial parameters, especially when very low amounts of
intracellular HCV RNA are expected’’. They further argue that ‘‘this
information has not been provided by the authors and it is impor-
tant to be sure that no false negative results have been obtained
due to the poor quality of the total RNA used in HCV RNA detec-
tion’’. This argument is true for HCV RNA detection by real-time
PCR in combination with extraction methods for isolation of total
nucleic acids. However, in this study, we used the isothermal TMA
assay combined with a HCV-speciﬁc RNA capture method in one
single reaction tube. Since cellular DNA and RNA were washed
out before starting the ampliﬁcation steps, total RNA cannot be
used for standardization of the sample input. With parallel
processing of an internal control, we were able tomonitor the efﬁ-
ciency of RNA capture and ampliﬁcation in each single reaction
tube. The main issue concerning HCV RNA detection in PBMC
was to reach at least the same analytical sensitivity compared to
HCV RNA detection in serum or plasma in order to exclude
false negative results. Therefore, we used a minimum input of
2.5 million PBMC representing approximately 2.0 to 2.5 ml
of whole blood, which corresponds to approximately 1.0 ml of
plasma (compared to 0.5 mlused forHCVRNAdetection in serum).
As far as sufﬁcient numbers of PBMC were available for individual
samples, a higher PBMC input could be used in order to improve
the analytical sensitivity for HCV RNA detection in the PBMC.
We fully agree with the authors that the incidence of occult
HCV infection found in our haemodialysis and kidney transplant
patients is not absolutely negligible. However, as also elaborated
in our paper, we would like to emphasize that the positive test
found in all our patients was weak positive. Furthermore, none
of these patients has developed any signs of liver disease nor
positive HCV RNA, even at the most recent mean follow up of
54 months in the two patients alive, suggesting that the weak
positive test for occult HCV infection found in these patients at
the onset may have been false positive. Furthermore, regarding
the authors’ argument that the lack of clinical relevance of occult
HCV infection cannot be assumed in these patients unless
absence of liver damage is demonstrated by transient elastogra-
phy, we would like to state that although non-invasive methods
like transient elastography have been shown to be reliable for the
diagnosis of cirrhosis, they are less accurate than liver biopsy in
discriminating different ﬁbrosis stages even in the non-transplantJournal of Hepatology 2014 vol. 61 j 1184–1191 1185
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Germany. Tel.: +49 30 450 553 373; fax: +49 30 450 553 916.setting [6]. Moreover, in HCV-infected kidney recipients, small
studies comparing the performance of non-invasive tests to liver
biopsies have shown inconsistent results [6]. Therefore, the util-
ity of such an expensive and laborious screening test to detect an
infection, which does not have any proven clinical consequences
is questionable.
In summary, data about the occult HCV infection in liver and/
or PBMCs despite negative HCV RNA in serum are conﬂicting.
Further well-designed longitudinal studies with serial analyses
for occult HCV infection from different geographic regions are
necessary to ﬁnally resolve this controversial issue.
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Leipzig, GermanyThe beginning of an end point: Peak AST in liver transplantation
To the Editor:
In their review on liver graft quality assessment during preserva-
tion, Verhoeven et al. [1] point out a painful weakness that contin-
ues to hamper progress in the ﬁeld of liver transplantation. The
lack of validated markers that reliably predict graft quality and
function make comparison of trial results and meta-analysis
impossible. There is an urgent need for international guidelines
on appropriate end points to assess liver graft quality and
function and the authors refer to early allograft dysfunction
(EAD) as described by Olthoff et al. [2] as a starting point. Indeed,
EAD and particularly peak aspartate transaminase (AST), one of
the EAD components, are increasingly used as primary end
point in liver transplantation trials aimed to improve (early)
graft function (e.g. ISRCTN00167887; ISRCTN39731134). When
determining the peak of a marker, it is essential that kinetics of
this marker and especially the timing of the peak be precisely
known so that determination of that peak can be as accurate as
possible. Although AST is a well-recognizedmarker for hepatocyte
injury and used as a surrogate to assess preservation and ische-
mia-reperfusion injury, it is remarkable how little information is
available on the kinetics of AST post-reperfusion. It is generally
assumed that AST peaks within the ﬁrst 24 to 72 h post-reperfu-
sion [3,4]. However, considering AST is released quickly from
injured hepatocytes and is also quite rapidly cleared, it is not
unthinkable that a peak – particularly an early one – might be
missed if samples are not precisely taken. We therefore deter-
mined the evolution of AST early post-reperfusion, and the timing
of its peak. In addition, we compared the peak AST and its timing
in timed post-reperfusion samples vs. routinely taken samples
(that are usually used to determine peak AST in clinical trials).
We analyzed post-reperfusion AST values in 66 adult liver-
only recipients (60 years [48–67], 38 males) transplanted
between 11/2011 and 11/2013 who had consented for a prospec-
tive observational study on kidney injury during liver transplan-
tation (NCT01333319, approved by the Ethics Committee). In this
study, plasma samples were taken at the time of incision, 30 min,
2 h, 6 h, and 12 h post-reperfusion. Furthermore, recipients had
routine AST determinations with a ﬁrst AST sample ‘‘at arrival
on the intensive care unit’’ and daily morning measures until
postoperative day (POD) 5. The post-reperfusion timing of these
routinely taken samples was retrospectively determined from
the electronic patient records. AST was determined in the central
lab of the hospital (coloric method, Hitachi/Roche Modular P).
Continuous variables (median [inter quartile range]) were com-
pared between timed and routine samples by the Mann-Whitney
U test (SPSS version 19).
Donors were on average 57 (44–68) years old and livers
were transplanted with a cold ischemia time of 6 h (5–8) and
1186 Journal of Hepatology 2014 vol. 61 j 1184–1191
